Processing .....please wait.. 
The article has been forwarded.... 
Ranbaxy launches a new generation anti-infective drug
Tuesday, 11 February 2003, 20:30 IST
NEW DELHI: India's leading pharmaceutical company Ranbaxy Laboratories Ltd has launched a high-end anti-infective oral product said to be useful in combating different types of bacteria in surgical cases and for respiratory tract infections.
The anti-infective product belonging to the advanced Cepholosporin category Cefprozil, under the brand name Refzil O, is being made available in India for the first time, the company said in a statement Monday.
"Refzil O, a high generation oral Cephalosporin, is useful in combating different types of bacteria in surgical cases and respiratory tract infections, both among adults and children," the statement said.
The brand will be a superior choice for the treatment of Staphyloccal infections and will be an ideal follow-up therapy for patients after usage of Ranbaxy's injectable Refzil.
"The launch of Refzil O further strengthens our position in the higher end Cephalosporins," said Malvinder Mohan Singh, India regional director of Ranbaxy Laboratories.
"The market for this product promises excellent potential and will help us in improving the market share in the Cephalosporin segment and widen the product portfolio."
The Cephalosporin market in India is currently estimated around 
10 billion, which is about one-third the anti-infectives market, and is growing at nine percent annually. The global market size of this molecule is around $400 million and is among the top five Cephalosporins out of more than 25 such molecules in this segment.
Source: IANS
10 billion, which is about one-third the anti-infectives market, and is growing at nine percent annually. The global market size of this molecule is around $400 million and is among the top five Cephalosporins out of more than 25 such molecules in this segment.
Source: IANS